Abstract
Purpose
To establish a continuous relationship between the size of various antibody fragments and their systemic clearance (CL) in mice.
Methods
Two different orthogonal approaches have been used to establish the relationship. First approach uses CL values estimated by non-compartmental analysis (NCA) to establish a correlation with protein size. The second approach simultaneously characterizes the PK data for all the proteins using a 2-compartment model to establish a relationship between protein size and pharmacokinetic (PK) parameters.
Results
Simple mathematical functions (e.g. sigmoidal, power law) were able to characterize the CL vs. protein size relationship generated using the investigated proteins. The relationship established in mouse was used to predict rat, rabbit, monkey, and human relationships using allometric scaling. The predicted relationships were found to capture the available spares data from each species reasonably well.
Conclusions
The CL vs. protein size relationship is important for establishing a robust quantitative structure-PK relationship (QSPKR) for protein therapeutics. The relationship presented here can help in a priori predicting plasma exposure of therapeutic proteins, and together with our previously established relationship between plasma and tissue concentrations of proteins, it can predict the tissue exposure of non-binding proteins simply based on molecular weight/radius and dose.
Similar content being viewed by others
Abbreviations
- BC:
-
Biodistribution Coefficient
- CL:
-
Systemic clearance
- MW:
-
Molecular weight
- NCA:
-
Non-compartmental analysis
- PK:
-
Pharmacokinetics
- QSPKR:
-
Quantitative structure-PK relationship
- TMDD:
-
Target Mediated Drug Disposition
References
Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–68.
Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58.
Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs. 2013;5(2):297–305.
Clayton NS, Emery NJ. What do jays know about other minds and other times? In: Berthoz A, Christen Y, editors. Neurobiology of Umwelt: how living beings perceive the world. research and perspectives in neurosciences. Berlin: Springer-Verlag; 2009. p. 109–23.
Venturoli D, Rippe B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol Renal Physiol. 2005;288(4):F605–F13.
Huh Y, Smith DE, Rose FM. Interspecies scaling and prediction of human clearance: comparison of small-and macro-molecule drugs. Xenobiotica. 2011;41(11):972–87.
Ober RJ, Martinez C, Vaccaro C, Zhou J, Ward ES. Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor. FcRn J Immunol. 2004;172(4):2021–9.
Glassman PM, Abuqayyas L, Balthasar JP. Assessments of antibody biodistribution. J Clin Pharmacol. 2015;55(S3):S29–38.
Waldmann T, Terry W. Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Investig. 1990;86(6):2093.
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32.
Mager DE, Mascelli MA, Kleiman NS, Fitzgerald DJ, Abernethy DR. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther. 2003;307(3):969–76.
Li Z, Krippendorff B-F, Sharma S, Walz AC, Lavé T, Shah DK. Influence of molecular size on tissue distribution of antibody fragments. MAbs. 2016;8(1):113–9.
Shah DK, Betts AM. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn. 2012;39(1):67–86.
Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861–71.
Bivona BJ, Park S, Harrison-Bernard LM. Glomerular filtration rate determinations in conscious type II diabetic mice. Am J Physiol Renal Physiol. 2011;300(3):F618–F25.
Norden AG, Lapsley M, Lee PJ, Pusey CD, Scheinman SJ, Tam FW, et al. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int. 2001;60(5):1885–92.
Paine SW, Ménochet K, Denton R, McGinnity DF, Riley RJ. Prediction of human renal clearance from preclinical species for a diverse set of drugs that exhibit both active secretion and net reabsorption. Drug Metab Dispos. 2011;39(6):1008–13.
Michigoshi Y, Katayama R, Yamagishi N, Kato M, Saito J, Satoh H, et al. Estimation of glomerular filtration rate in rabbits by a single-sample method using iodixanol. Lab Anim. 2012;46(4):341–4.
Iwama R, Tsubasa S, Sakurai K, Takasuna K, Ichijo T, Furuhama K, et al. Estimation of glomerular filtration rate in cynomolgus monkeys (Macaca fascicularis). J Vet Med Sci. 2014;76(10):1423.
Shah DK. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J Pharmacokinet Pharmacodyn. 2015;42(5):553–71.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Supplementary Table 1
(DOCX 31 kb)
Supplementary Table 2
(DOCX 93 kb)
Rights and permissions
About this article
Cite this article
Li, Z., Krippendorff, BF. & Shah, D.K. Influence of Molecular size on the clearance of antibody fragments. Pharm Res 34, 2131–2141 (2017). https://doi.org/10.1007/s11095-017-2219-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-017-2219-y